noscript

News and Announcements

Proteomics Granted US Patent for Diagnostic Test

  • Published October 28, 2015 6:30PM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

27th October 2015, ASX Announcement

  • Grant of US patent is a critical milestone in the development of the Diagnostic Test for Diabetic Kidney Disease in the world’s largest health care market
  • Patent provides protection as both a predictive and diagnostic test in the USA
  • Ability to accurately detect early onset of Diabetic Kidney Disease via a simple blood test has the potential to save health care systems globally $100s of millions annually

Life sciences company Proteomics International Laboratories Ltd (ASX:PIQ) (the Company, PILL) is pleased to announce it has been granted a US patent for its PromarkerD Diagnostic Test for the early diagnosis of diabetic kidney disease (DKD).

The patent provides protection for the use of PromarkerD as both a predictive (prognostic) and diagnostic test in the USA, and is valid until 20 September 2031. The patent entitled, “Method of assessing diabetic nephropathy using CD5 antigen-like “(patent number: US 9,146,243 B2).

To read the full announcement, please click here

 

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now